Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Abstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA).Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA.JIA- and uveitis-related data, including intraocular inf